What is the recommended management for a patient with a history of nephroureterectomy for renal cell carcinoma who now has hypophosphatemia, anemia, markedly elevated free kappa light chains, and a 19‑lb weight loss over the past year?

Management of Suspected Recurrent Renal Cell Carcinoma with Concurrent Plasma Cell Dyscrasia

This patient requires urgent evaluation for both metastatic/recurrent renal cell carcinoma AND a plasma cell disorder (likely multiple myeloma or light chain disease), with the markedly elevated free kappa light chains (24.1 mg/dL, normal <1.94) being the most critical finding that demands immediate hematologic workup and treatment.

Immediate Diagnostic Workup

For Plasma Cell Disorder (Priority #1)

• Serum protein electrophoresis with immunofixation to evaluate for monoclonal protein 1
• Complete serum free light chain analysis including kappa/lambda ratio (the elevated kappa at 24.1 is highly abnormal and suggests light chain multiple myeloma) 2, 3
• 24-hour urine collection for protein electrophoresis and immunofixation to assess urinary light chain excretion 1
• Bone marrow biopsy with aspirate to quantify plasma cell percentage and assess for clonality 4, 3
• Skeletal survey or whole-body low-dose CT to evaluate for lytic bone lesions 4
• Serum calcium, LDH, beta-2 microglobulin, and albumin for ISS staging 4
• FISH for high-risk cytogenetics including t(4;14), t(14;16), t(14;20), del(17p), and 1q gain 4

For Renal Cell Carcinoma Recurrence

• Contrast-enhanced CT of chest, abdomen, and pelvis for staging and detection of metastatic disease 1
• Comprehensive metabolic panel including creatinine, corrected calcium, and LDH 1

Critical Clinical Context

The constellation of findings strongly suggests light chain multiple myeloma with cast nephropathy:

• Markedly elevated free kappa light chains (>10x upper limit of normal) 2, 3
• Hypophosphatemia (likely from renal tubular dysfunction) 5
• Mild anemia (RBC 4.12, likely lower than baseline) 6
• Significant weight loss (19 lbs/year) 4, 3
• History of nephroureterectomy creating single kidney vulnerability 7

Management Algorithm Based on Diagnosis

If Light Chain Multiple Myeloma is Confirmed

Immediate interventions (within 24-48 hours):

1. Aggressive hydration with IV fluids targeting urine output of 100-150 mL/hour to reduce tubular light chain concentration 7

2. Initiate bortezomib-based chemotherapy immediately (do not wait for complete staging):

   • Bortezomib + dexamethasone is the preferred regimen for patients with renal impairment as bortezomib does not require dose adjustment and can reverse renal failure 4, 7
   • Alternative: VRd (bortezomib, lenalidomide with dose adjustment, dexamethasone) if patient is transplant-eligible 4

3. Consider therapeutic plasma exchange (TPE) if:

   • Serum free light chains remain >1,500 mg/dL after initial chemotherapy 8
   • Progressive renal failure despite hydration and chemotherapy 8
   • Evidence of cast nephropathy on renal biopsy 8, 9
   • TPE can reduce kappa FLC by >70% within days but requires multiple procedures 8

4. High-cutoff hemodialysis may be superior to standard plasma exchange for light chain removal if available (HCO 1100 membrane achieves 40.8% reduction rate per session) 9

5. Correct hypophosphatemia:

   • For severe hypophosphatemia (<1.0 mg/dL): IV phosphate repletion 5
   • For moderate hypophosphatemia: oral phosphate supplementation 5

6. Manage anemia:

   • Avoid ESAs in patients with active or recent cancer history due to increased mortality risk 6
   • Consider red blood cell transfusion if symptomatic or hemoglobin <7-8 g/dL 6
   • Iron supplementation if iron deficient 6

If Metastatic/Recurrent RCC is Confirmed

Risk stratification is essential using IMDC or MSKCC criteria (performance status, time from diagnosis to treatment, hemoglobin, calcium, neutrophils, platelets) 1.

First-line systemic therapy options:

• For intermediate/poor-risk patients: Nivolumab + ipilimumab is recommended 1
• Alternative for intermediate/poor-risk: Cabozantinib monotherapy 1
• For good-risk patients: VEGF-targeted TKIs (sunitinib, pazopanib) or tivozanib 1

If this represents second-line therapy (assuming prior nephroureterectomy was for metastatic disease):

• Nivolumab is the preferred option after prior TKI therapy 1
• Cabozantinib is an alternative second-line option 1

Concurrent Disease Management

If both diagnoses coexist (which is possible given the clinical presentation):

1. Prioritize treatment of the plasma cell disorder first as it is immediately life-threatening with potential for irreversible renal failure 7, 8

2. Bortezomib-based myeloma therapy should be initiated within 24-48 hours of diagnosis 4, 7

3. Delay RCC systemic therapy until:

   • Renal function stabilizes 7
   • Light chain levels decrease significantly 8
   • Patient's performance status improves 1

4. Avoid nephrotoxic RCC therapies in the setting of myeloma-related renal impairment:

   • TKIs require dose adjustment with renal dysfunction 10
   • Checkpoint inhibitors may be safer but monitor closely 1

Critical Pitfalls to Avoid

• Do not delay chemotherapy waiting for complete staging in suspected light chain myeloma with renal impairment—every day counts for renal recovery 4, 7, 8
• Do not use standard free light chain reference ranges in patients with renal dysfunction (use eGFR-adjusted ranges: 0.46-2.62 for eGFR 45-59) 2
• Do not assume hypophosphatemia is solely from renal wasting—it may indicate Fanconi syndrome from light chain toxicity 5
• Do not use ESAs for anemia management in patients with active or recent malignancy 6
• Do not start plasma exchange without concurrent chemotherapy—mechanical removal alone is insufficient 8, 9

Supportive Care Essentials

• Bisphosphonates (pamidronate or zoledronic acid with dose adjustment for renal function) if bone lesions present 1, 7
• Avoid nephrotoxic medications including NSAIDs, IV contrast when possible, and aminoglycosides 7
• Monitor for tumor lysis syndrome after initiating chemotherapy, especially with high tumor burden 8
• Correct hypercalcemia if present with hydration and bisphosphonates 7